[EN] METHOD FOR INHIBITING TRYPANSOMA CRUZI<br/>[FR] PROCÉDÉ D'INHIBITION DE TRYPANSOMA CRUZI
申请人:UNIV HOWARD
公开号:WO2013016661A1
公开(公告)日:2013-01-31
In its broadest aspect, a method for treating a mammalian patient at risk or suffering from a disease caused by a kinetoplastid parasite comprises administering to such subject an effective kinetoplasticidal amount of an imido-substituted 1,4- naphthoquinone to inhibit the kinetoplastid. In an important aspect, a method of inhibiting Trypanosoma cruzi comprises administering to a patient for prophylaxis or to a patient in need of treatment an antitrypanosomal effective amount of an imido-substituted 1 A-naphthoquinone.
Methods are provided to inhibit proliferation of Trypanosoma cruzi with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
Methods are provided to inhibit proliferation of
Trypanosoma cruzi
with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against Chagas disease.
VITAMIN C AND VITAMIN K COMPOUND FOR TREATING PANCREATIC CANCER
申请人:IC-MedTech Corp.
公开号:US20170333392A1
公开(公告)日:2017-11-23
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of pancreatic cancer in a subject, comprising administering to the subject therapeutically effective amounts of (i) vitamin C, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a vitamin K compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE
申请人:IC-MedTech Corp.
公开号:US20190343794A1
公开(公告)日:2019-11-14
Provided herein is a method of treating, preventing, or alleviating one or more symptoms of Chagas disease in a subject, comprising administering to the subject (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.